All In Biotech

Drug Trial Radar · NCT07630727

Study of AHB-171 in Chronic Hepatitis B Participants

An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Jun 24, 2026

Primary completion

Mar 31, 2029

Study completion May 31, 2029

Sponsor

Lead sponsor
Ausper Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)

Conditions

  • Hepatitis B, Chronic (CHB)

Interventions

  • AHB-171 InjectionDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with HBsAg <10 IU/mL and HBV DNA < LLOQ (10 IU/mL)Time frame: Up to 90 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • AusperBio Investigational Site

    Beijing, Beijing Municipality, China · Recruiting

  • AusperBio Investigational Site

    Chongqing, Chongqing Municipality, China · Recruiting

  • AusperBio Investigational Site

    Xiamen, Fujian, China · Recruiting

  • AusperBio Investigational Site

    Guangzhou, Guangdong, China · Recruiting

  • AusperBio Investigational Site

    Nanning, Guangxi, China · Recruiting

  • AusperBio Investigational Site

    Zhengzhou, Henan, China · Recruiting

  • AusperBio Investigational Site

    Changzhou, Jiangsu, China · Recruiting

  • AusperBio Investigational Site

    Jilin City, Jilin, China · Recruiting

  • AusperBio Investigational Site

    Chengdu, Sichuang, China · Recruiting

  • AusperBio Investigational Site

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.